These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35355244)

  • 41. Constructing multiple test procedures for partially ordered hypothesis sets.
    Edwards D; Madsen J
    Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches.
    Ozga AK; Rauch G
    BMC Med Res Methodol; 2022 Feb; 22(1):38. PubMed ID: 35123397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A less conservative method to adjust for familywise error rate in neuropsychological research: the Holm's sequential Bonferroni procedure.
    Eichstaedt KE; Kovatch K; Maroof DA
    NeuroRehabilitation; 2013; 32(3):693-6. PubMed ID: 23648625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sample size determination for equivalence assessment with multiple endpoints.
    Sun A; Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1203-14. PubMed ID: 25032845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A modified varying-stage adaptive phase II/III clinical trial design.
    Dong G; Vandemeulebroecke M
    Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential parallel comparison design with two coprimary endpoints.
    Homma G; Daimon T
    Pharm Stat; 2020 May; 19(3):243-254. PubMed ID: 31829521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints.
    Yang J; Li J; Wang S; Luo L; Liu P
    Hum Vaccin Immunother; 2019; 15(1):256-263. PubMed ID: 30273507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and analysis of three-arm trials with negative binomially distributed endpoints.
    Mütze T; Munk A; Friede T
    Stat Med; 2016 Feb; 35(4):505-21. PubMed ID: 26388314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating co-primary endpoints collectively in clinical trials.
    Li QH
    Biom J; 2009 Feb; 51(1):137-45. PubMed ID: 19219905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A method for testing a prespecified subgroup in clinical trials.
    Song Y; Chi GY
    Stat Med; 2007 Aug; 26(19):3535-49. PubMed ID: 17266164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reliably picking the best endpoint.
    Follmann D
    Stat Med; 2018 Dec; 37(29):4374-4385. PubMed ID: 30091264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some controversial multiple testing problems in regulatory applications.
    Hung HM; Wang SJ
    J Biopharm Stat; 2009; 19(1):1-11; discussion 12-41. PubMed ID: 19127460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of multiple endpoint dependency on Q and I(2) in meta-analysis.
    Thompson CG; Becker BJ
    Res Synth Methods; 2014 Sep; 5(3):235-53. PubMed ID: 26052849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sample sizes for trials involving multiple correlated must-win comparisons.
    Julious SA; McIntyre NE
    Pharm Stat; 2012; 11(2):177-85. PubMed ID: 22383136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Rejection Principle for Sequential Tests of Multiple Hypotheses Controlling Familywise Error Rates.
    Bartroff J; Song J
    Scand Stat Theory Appl; 2016 Mar; 31(1):3-19. PubMed ID: 26985125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of type I error rate associated with dose-group switching in a longitudinal Alzheimer trial.
    Habteab Ghebretinsae A; Molenberghs G; Dmitrienko A; Offen W; Sethuraman G
    J Biopharm Stat; 2014; 24(3):660-84. PubMed ID: 24697817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.